Riboflavin lowers blood pressure in cardiovascular disease patients homozygous for the 677C→T polymorphism in MTHFR

Objective The purpose was to examine the effect of intervention with riboflavin (a cofactor for MTHFR) on blood pressure in patients homozygous (TT genotype) for the common 677C→T polymorphism in MTHFR. Methods We investigated 197 premature cardiovascular disease patients, prescreened for the MTHFR 677C→T polymorphism, from an original cohort of 404 to select those with the TT genotype (n = 60) and a similar number with heterozygous (CT; n = 85) or wild-type (CC; n = 75) genotypes. Of these, 181 completed an intervention in which participants were randomized within each genotype group to receive 1.6 mg per day riboflavin or placebo for 16 weeks. Results Among patients taking one or more antihypertensive drugs at recruitment (82%), we observed that target blood pressure (<140/90 mmHg) had been achieved in only 37% patients with the TT genotype compared with 59% with the CT and 64% with the CC genotype (P < 0.001). Riboflavin intervention reduced mean blood pressure specifically in those with the TT genotype (from 144/87 to 131/80 mmHg; P < 0.05 systolic; P < 0.05 diastolic), with no response observed in the other genotype groups. Conclusion Riboflavin is effective in reducing blood pressure specifically in patients with the MTHFR 677 TT genotype. The findings, if confirmed, may have important implications for the prevention and treatment of hypertension.

[1]  S. Vollset,et al.  Geographical and ethnic variation of the 677C>T allele of 5,10 methylenetetrahydrofolate reductase (MTHFR): findings from over 7000 newborns from 16 areas world wide , 2003, Journal of medical genetics.

[2]  Sheila M. Williams,et al.  Lowering homocysteine with B vitamins has no effect on blood pressure in older adults. , 2007, The Journal of nutrition.

[3]  A. Dart,et al.  Folic acid supplementation for 3 wk reduces pulse pressure and large artery stiffness independent of MTHFR genotype. , 2005, The American journal of clinical nutrition.

[4]  Zhoutao Chen,et al.  Effects of common polymorphisms on the properties of recombinant human methylenetetrahydrofolate reductase , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[5]  J. Scott,et al.  Microbiological assay for serum, plasma, and red cell folate using cryopreserved, microtiter plate method. , 1997, Methods in enzymology.

[6]  J. Twisk,et al.  Long-Term Homocysteine-Lowering Treatment With Folic Acid Plus Pyridoxine Is Associated With Decreased Blood Pressure but Not With Improved Brachial Artery Endothelium-Dependent Vasodilation or Carotid Artery Stiffness: A 2-Year, Randomized, Placebo-Controlled Trial , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[7]  R. Collins,et al.  Blood pressure, stroke, and coronary heart disease Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias , 1990, The Lancet.

[8]  I. Rosenberg,et al.  Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. , 1996, Circulation.

[9]  R. Heshmat,et al.  Plasma homocysteine concentration and blood pressure in healthy Iranian adults: the Tehran Homocysteine Survey (2003–2004) , 2005, Journal of Human Hypertension.

[10]  A. Leino.  Fully automated measurement of total homocysteine in plasma and serum on the Abbott IMx analyzer. , 1999, Clinical chemistry.

[11]  S. Vollset,et al.  The methylenetetrahydrofolate reductase 677C-->T polymorphism as a modulator of a B vitamin network with major effects on homocysteine metabolism. , 2007, American journal of human genetics.

[12]  T. Ogihara,et al.  Association of Methylenetetrahydrofolate Reductase Gene Polymorphism With Carotid Atherosclerosis Depending on Smoking Status in a Japanese General Population , 2003, Stroke.

[13]  S. Lewis,et al.  Meta-analysis of MTHFR 677C→ T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate? , 2005, BMJ : British Medical Journal.

[14]  S. Yusuf,et al.  Homocysteine lowering with folic acid and B vitamins in vascular disease. , 2006, The New England journal of medicine.

[15]  B. Tabachnick,et al.  Using Multivariate Statistics , 1983 .

[16]  Xiping Xu,et al.  Efficacy of folic acid supplementation in stroke prevention: a meta-analysis , 2007, The Lancet.

[17]  Liakishev Aa.  Homocysteine lowering with folic acid and B vitamins in vascular disease , 2006 .

[18]  A M Prentice,et al.  The relative effectiveness of iron and iron with riboflavin in correcting a microcytic anaemia in men and children in rural Gambia. , 1983, Human nutrition. Clinical nutrition.

[19]  H. McNulty,et al.  Riboflavin Lowers Homocysteine in Individuals Homozygous for the MTHFR 677C→T Polymorphism , 2005, Circulation.

[20]  Daniel W. Jones,et al.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.

[21]  D. Levy,et al.  Plasma Homocysteine, Hypertension Incidence, and Blood Pressure Tracking: The Framingham Heart Study , 2003, Hypertension.

[22]  J. Higaki,et al.  Methylenetetrahydrofolate reductase gene polymorphism: relation to blood pressure and cerebrovascular disease. , 1998, American journal of hypertension.

[23]  A. Smith,et al.  Total Plasma Homocysteine, Age, Systolic Blood Pressure, and Cognitive Performance in Older People , 2002, Journal of the American Geriatrics Society.

[24]  A. Prentice,et al.  Plasma pyridoxal phosphate and pyridoxic acid and their relationship to plasma homocysteine in a representative sample of British men and women aged 65 years and over , 1999, British Journal of Nutrition.

[25]  Sc Prospective,et al.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002 .

[26]  L. Chambless,et al.  Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. , 2004, JAMA.

[27]  Riboflavin Lowers Homocysteine in Individuals Homozygous for the MTHFR 677C→T Polymorphism , 2005 .

[28]  R. Collins,et al.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002, The Lancet.

[29]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[30]  A. Dart,et al.  Folic acid supplementation for 3 wk reduces pulse pressure and large artery stiffness independent of MTHFR genotype , 2005 .

[31]  T. Lancet.  Hypertension: uncontrolled and conquering the world , 2007, The Lancet.

[32]  D. Lu,et al.  A meta-analysis of association between C677T polymorphism in the methylenetetrahydrofolate reductase gene and hypertension , 2007, European Journal of Human Genetics.

[33]  R. Matthews,et al.  A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase , 1995, Nature Genetics.

[34]  P. Cassano,et al.  Homocysteine and blood pressure in the Third National Health and Nutrition Examination Survey, 1988-1994. , 2002, American journal of epidemiology.

[35]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[36]  S. Vollset,et al.  Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. , 1995, JAMA.

[37]  S. Vollset,et al.  Riboflavin as a determinant of plasma total homocysteine: effect modification by the methylenetetrahydrofolate reductase C677T polymorphism. , 2000, Clinical chemistry.

[38]  D. Wald,et al.  Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis , 2002, BMJ : British Medical Journal.

[39]  K. Sutton-Tyrrell,et al.  High homocysteine levels are independently related to isolated systolic hypertension in older adults. , 1997, Circulation.

[40]  Stephen H. D. Jackson,et al.  Folic acid enhances endothelial function and reduces blood pressure in smokers: a randomized controlled trial , 2002, Journal of internal medicine.

[41]  Per Magne Ueland,et al.  Homocysteine lowering and cardiovascular events after acute myocardial infarction. , 2006, The New England journal of medicine.

[42]  T. Niu,et al.  The C677T polymorphism of the methylenetetrahydrofolate reductase gene is associated with the level of decrease on diastolic blood pressure in essential hypertension patients treated by angiotensin-converting enzyme inhibitor. , 2004, Thrombosis research.

[43]  H. McNulty,et al.  Impaired functioning of thermolabile methylenetetrahydrofolate reductase is dependent on riboflavin status: implications for riboflavin requirements. , 2002, The American journal of clinical nutrition.

[44]  Petra Verhoef,et al.  MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta-analysis. , 2002, JAMA.

[45]  E. Rimm,et al.  Folate Intake and the Risk of Incident Hypertension Among US Women , 2006 .

[46]  R. Ravazzolo,et al.  5,10-Methylenetetrahydrofolate reductase polymorphism and early organ damage in primary hypertension. , 2001, American journal of hypertension.

[47]  C. Yunis,et al.  The Effect of Methylenetetrahydrofolate Reductase C677T Common Variant on Hypertensive Risk Is Not Solely Explained by Increased Plasma Homocysteine Values , 2003, Clinical and experimental hypertension.

[48]  B. Kelleher,et al.  Microbiological assay for vitamin B12 performed in 96-well microtitre plates. , 1991, Journal of clinical pathology.